Uniqure announces dosing of first patient in gentle phase i/iia clinical trial of amt-260 for the treatment of refractory mesial temporal lobe epilepsy

Lexington, mass. and amsterdam, nov. 21, 2024 (globe newswire) -- uniqure n.v. (nasdaq: qure), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first patient has been dosed in the gentle phase i/iia clinical trial of amt-260 for the treatment of refractory mesial temporal lobe epilepsy (mtle).
AMT Ratings Summary
AMT Quant Ranking